Cargando…
CD38 in Advanced Prostate Cancers
BACKGROUND: CD38, a druggable ectoenzyme, is involved in the generation of adenosine, which is implicated in tumour immune evasion. Its expression and role in prostate tumour-infiltrating immune cells (TIICs) have not been elucidated. OBJECTIVE: To characterise CD38 expression on prostate cancer (PC...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier Science
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8175332/ https://www.ncbi.nlm.nih.gov/pubmed/33678520 http://dx.doi.org/10.1016/j.eururo.2021.01.017 |
_version_ | 1783703032573198336 |
---|---|
author | Guo, Christina Crespo, Mateus Gurel, Bora Dolling, David Rekowski, Jan Sharp, Adam Petremolo, Antonella Sumanasuriya, Semini Rodrigues, Daniel N. Ferreira, Ana Pereira, Rita Figueiredo, Ines Mehra, Niven Lambros, Maryou B.K. Neeb, Antje Gil, Veronica Seed, George Terstappen, Leon Alimonti, Andrea Drake, Charles G. Yuan, Wei de Bono, Johann S. |
author_facet | Guo, Christina Crespo, Mateus Gurel, Bora Dolling, David Rekowski, Jan Sharp, Adam Petremolo, Antonella Sumanasuriya, Semini Rodrigues, Daniel N. Ferreira, Ana Pereira, Rita Figueiredo, Ines Mehra, Niven Lambros, Maryou B.K. Neeb, Antje Gil, Veronica Seed, George Terstappen, Leon Alimonti, Andrea Drake, Charles G. Yuan, Wei de Bono, Johann S. |
author_sort | Guo, Christina |
collection | PubMed |
description | BACKGROUND: CD38, a druggable ectoenzyme, is involved in the generation of adenosine, which is implicated in tumour immune evasion. Its expression and role in prostate tumour-infiltrating immune cells (TIICs) have not been elucidated. OBJECTIVE: To characterise CD38 expression on prostate cancer (PC) epithelial cells and TIICs, and to associate this expression with clinical outcomes. DESIGN, SETTING, AND PARTICIPANTS: RNAseq from 159 patients with metastatic castration-resistant prostate cancer (mCRPC) in the International Stand Up To Cancer/Prostate Cancer Foundation (SU2C/PCF) cohort and 171 mCRPC samples taken from 63 patients in the Fred Hutchinson Cancer Research Centre cohort were analysed. CD38 expression was immunohistochemically scored by a validated assay on 51 castration-resistant PC (CRPC) and matching, same-patient castration-sensitive PC (CSPC) biopsies obtained between 2016 and 2018, and was associated with retrospectively collected clinical data. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: mCRPC transcriptomes were analysed for associations between CD38 expression and gene expression signatures. Multiplex immunofluorescence determined CD38 expression in PC biopsies. Differences in CD38(+) TIIC densities between CSPC and CRPC biopsies were analysed using a negative binomial mixed model. Differences in the proportions of CD38(+) epithelial cells between non-matched benign prostatic epithelium and PC were compared using Fisher’s exact test. Differences in the proportions of biopsies containing CD38(+) tumour epithelial cells between matched CSPC and CRPC biopsies were compared by McNemar’s test. Univariable and multivariable survival analyses were performed using Cox regression models. RESULTS AND LIMITATIONS: CD38 mRNA expression in mCRPC was most significantly associated with upregulated immune signalling pathways. CD38 mRNA expression was associated with interleukin (IL)-12, IL-23, and IL-27 signalling signatures as well as immunosuppressive adenosine signalling and T cell exhaustion signatures. CD38 protein was frequently expressed on phenotypically diverse TIICs including B cells and myeloid cells, but largely absent from tumour epithelial cells. CD38(+) TIIC density increased with progression to CRPC and was independently associated with worse overall survival. Future studies are required to dissect TIIC CD38 function. CONCLUSIONS: CD38(+) prostate TIICs associate with worse survival and immunosuppressive mechanisms. The role of CD38 in PC progression warrants investigation as insights into its functions may provide rationale for CD38 targeting in lethal PC. PATIENT SUMMARY: CD38 is expressed on the surface of white blood cells surrounding PC cells. These cells may impact PC growth and treatment resistance. Patients with PC with more CD38-expressing white blood cells are more likely to die earlier. |
format | Online Article Text |
id | pubmed-8175332 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Elsevier Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-81753322021-06-05 CD38 in Advanced Prostate Cancers Guo, Christina Crespo, Mateus Gurel, Bora Dolling, David Rekowski, Jan Sharp, Adam Petremolo, Antonella Sumanasuriya, Semini Rodrigues, Daniel N. Ferreira, Ana Pereira, Rita Figueiredo, Ines Mehra, Niven Lambros, Maryou B.K. Neeb, Antje Gil, Veronica Seed, George Terstappen, Leon Alimonti, Andrea Drake, Charles G. Yuan, Wei de Bono, Johann S. Eur Urol Platinum Priority – Prostate Cancer BACKGROUND: CD38, a druggable ectoenzyme, is involved in the generation of adenosine, which is implicated in tumour immune evasion. Its expression and role in prostate tumour-infiltrating immune cells (TIICs) have not been elucidated. OBJECTIVE: To characterise CD38 expression on prostate cancer (PC) epithelial cells and TIICs, and to associate this expression with clinical outcomes. DESIGN, SETTING, AND PARTICIPANTS: RNAseq from 159 patients with metastatic castration-resistant prostate cancer (mCRPC) in the International Stand Up To Cancer/Prostate Cancer Foundation (SU2C/PCF) cohort and 171 mCRPC samples taken from 63 patients in the Fred Hutchinson Cancer Research Centre cohort were analysed. CD38 expression was immunohistochemically scored by a validated assay on 51 castration-resistant PC (CRPC) and matching, same-patient castration-sensitive PC (CSPC) biopsies obtained between 2016 and 2018, and was associated with retrospectively collected clinical data. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: mCRPC transcriptomes were analysed for associations between CD38 expression and gene expression signatures. Multiplex immunofluorescence determined CD38 expression in PC biopsies. Differences in CD38(+) TIIC densities between CSPC and CRPC biopsies were analysed using a negative binomial mixed model. Differences in the proportions of CD38(+) epithelial cells between non-matched benign prostatic epithelium and PC were compared using Fisher’s exact test. Differences in the proportions of biopsies containing CD38(+) tumour epithelial cells between matched CSPC and CRPC biopsies were compared by McNemar’s test. Univariable and multivariable survival analyses were performed using Cox regression models. RESULTS AND LIMITATIONS: CD38 mRNA expression in mCRPC was most significantly associated with upregulated immune signalling pathways. CD38 mRNA expression was associated with interleukin (IL)-12, IL-23, and IL-27 signalling signatures as well as immunosuppressive adenosine signalling and T cell exhaustion signatures. CD38 protein was frequently expressed on phenotypically diverse TIICs including B cells and myeloid cells, but largely absent from tumour epithelial cells. CD38(+) TIIC density increased with progression to CRPC and was independently associated with worse overall survival. Future studies are required to dissect TIIC CD38 function. CONCLUSIONS: CD38(+) prostate TIICs associate with worse survival and immunosuppressive mechanisms. The role of CD38 in PC progression warrants investigation as insights into its functions may provide rationale for CD38 targeting in lethal PC. PATIENT SUMMARY: CD38 is expressed on the surface of white blood cells surrounding PC cells. These cells may impact PC growth and treatment resistance. Patients with PC with more CD38-expressing white blood cells are more likely to die earlier. Elsevier Science 2021-06 /pmc/articles/PMC8175332/ /pubmed/33678520 http://dx.doi.org/10.1016/j.eururo.2021.01.017 Text en © 2021 The Author(s) https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Platinum Priority – Prostate Cancer Guo, Christina Crespo, Mateus Gurel, Bora Dolling, David Rekowski, Jan Sharp, Adam Petremolo, Antonella Sumanasuriya, Semini Rodrigues, Daniel N. Ferreira, Ana Pereira, Rita Figueiredo, Ines Mehra, Niven Lambros, Maryou B.K. Neeb, Antje Gil, Veronica Seed, George Terstappen, Leon Alimonti, Andrea Drake, Charles G. Yuan, Wei de Bono, Johann S. CD38 in Advanced Prostate Cancers |
title | CD38 in Advanced Prostate Cancers |
title_full | CD38 in Advanced Prostate Cancers |
title_fullStr | CD38 in Advanced Prostate Cancers |
title_full_unstemmed | CD38 in Advanced Prostate Cancers |
title_short | CD38 in Advanced Prostate Cancers |
title_sort | cd38 in advanced prostate cancers |
topic | Platinum Priority – Prostate Cancer |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8175332/ https://www.ncbi.nlm.nih.gov/pubmed/33678520 http://dx.doi.org/10.1016/j.eururo.2021.01.017 |
work_keys_str_mv | AT guochristina cd38inadvancedprostatecancers AT crespomateus cd38inadvancedprostatecancers AT gurelbora cd38inadvancedprostatecancers AT dollingdavid cd38inadvancedprostatecancers AT rekowskijan cd38inadvancedprostatecancers AT sharpadam cd38inadvancedprostatecancers AT petremoloantonella cd38inadvancedprostatecancers AT sumanasuriyasemini cd38inadvancedprostatecancers AT rodriguesdanieln cd38inadvancedprostatecancers AT ferreiraana cd38inadvancedprostatecancers AT pereirarita cd38inadvancedprostatecancers AT figueiredoines cd38inadvancedprostatecancers AT mehraniven cd38inadvancedprostatecancers AT lambrosmaryoubk cd38inadvancedprostatecancers AT neebantje cd38inadvancedprostatecancers AT gilveronica cd38inadvancedprostatecancers AT seedgeorge cd38inadvancedprostatecancers AT terstappenleon cd38inadvancedprostatecancers AT alimontiandrea cd38inadvancedprostatecancers AT drakecharlesg cd38inadvancedprostatecancers AT yuanwei cd38inadvancedprostatecancers AT debonojohanns cd38inadvancedprostatecancers AT cd38inadvancedprostatecancers |